drugset / Trial / NCT05877547
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Timeline
- Start
- 2023-06-23
- Primary completion
- 2025-12-29
- Completion
- 2025-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efinopegdutide | Protein / enzyme biologic | 4 mg | Subcutaneous |
| Subject | Efinopegdutide | Protein / enzyme biologic | 7 mg | Subcutaneous |
| Subject | Efinopegdutide | Protein / enzyme biologic | 10 mg | Subcutaneous |
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |